The role of an immune checkpoint score in resected non-small cell lung cancer patients’ prognosis

Rossana Berardi, Silvia Rinaldi

Abstract

Lung cancer is the leading cause of cancer related death in both sex and its incidence is still increasing. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers (1). Despite many treatment options are available, most of NSCLC patients’ diagnoses are reached in advanced stages and their prognosis remains poor. Over the past few years, a variety of prognostic and predictive factors have been investigated in patients with NSCLC, and several prognostic models have been proposed to predict the outcome of patients with NSCLC (2).